C-CAR-011

BIOLOGICAL2 trials

Sponsors

Shanghai AbelZeta Ltd.

Conditions

Refractory Diffuse Large B-Cell LymphomaRelapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

CompletedNCT02976857

Shanghai AbelZeta Ltd.Refractory Diffuse Large B-Cell Lymphoma

Start: 2016-12-31End: 2019-01-09Target: 15Updated: 2019-01-17

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Shanghai AbelZeta Ltd.Relapsed or Refractory Acute Lymphoblastic Leukemia

Start: 2017-01-31End: 2018-11-30Target: 20Updated: 2017-01-20

Related Papers

THE ROLES OF PET/CT IN PREDICTING THE PROGNOSIS OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TREATED PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

Hematological Oncology2019-06-011 citations